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RNA binding proteins and signaling components
control the production of pro-death and pro-survival
splice variants of Bcl-x. DNA damage promoted by
oxaliplatin increases the level of pro-apoptotic Bcl-
xS in an ATM/CHK2-dependent manner, but how
this shift is enforced is not known. Here, we show
that in normally growing cells, when the 50 splice
site of Bcl-xS is largely repressed, SRSF10 partially
relieves repression and interacts with repressor
hnRNP K and stimulatory hnRNP F/H proteins. Oxa-
liplatin abrogates the interaction of SRSF10 with
hnRNP F/H and decreases the association of
SRSF10 and hnRNP K with the Bcl-x pre-mRNA.
Dephosphorylation of SRSF10 is linked with these
changes. A broader analysis reveals that DNA dam-
age co-opts SRSF10 to control splicing decisions in
transcripts encoding components involved in DNA
repair, cell-cycle control, and apoptosis. DNA dam-
age therefore alters the interactions between splicing
regulators to elicit a splicing response that deter-
mines cell fate.
INTRODUCTION
Programmed cell death or apoptosis plays a critical role during
animal development and in maintenance of homeostasis (Clave-
rı´a et al., 2013). Cancer cells often display resistance to signals
that elicit apoptosis, yet many anti-cancer strategies aim to
generate sufficient DNA damage to override this barrier and ulti-
mately trigger cell death. To design more efficient anti-cancer
approaches that will bypass these hurdles, a better understand-
ing of the pathways and molecular mechanisms that lead to
apoptosis is required. The function of several apoptotic regula-
tors and effectors is often regulated by alternative splicing to
produce variants with activities ranging from pro-apoptotic to1990 Cell Reports 17, 1990–2003, November 15, 2016 ª 2016 The A
This is an open access article under the CC BY license (http://creativepro-survival (Schwerk and Schulze-Osthoff, 2005). At least
some of these splicing decisions are coordinated by factors
involved in cell-cycle control (Moore et al., 2010). Moreover,
DNA damage can reprogram splicing decisions in a variety of
cell fate-associated genes including several involved in
apoptosis (Dutertre et al., 2014; Naro et al., 2015; Shkreta and
Chabot, 2015). For example, DNA damage caused by the topo-
isomerase inhibitor camptothecin or UV irradiation alters the ac-
tivity of the Ewing sarcoma protein EWS to affect the alternative
splicing of the p53 repressor MDM2 (Dutertre et al., 2010), the
FAS/CD95 receptor (Paronetto et al., 2014), and genes involved
in DNA repair (Paronetto et al., 2011). DNA damage also triggers
the formation of a complex between BRCA1 and splicing factors
that localizes at DNA repair genes to stimulate co-transcriptional
splicing (Savage et al., 2014).
Studies aimed at uncovering regulatory principles of splicing
control in apoptotic genes have revealed the contribution of
multiple regulators. This is well illustrated with the Bcl-x gene
(BCL2L1), which produces through the use of competing alterna-
tive 50 splice sites (50ss), the pro-survival Bcl-xL and the pro-
apoptotic Bcl-xS splice variants (Schwerk and Schulze-Osthoff,
2005). More than a dozen splicing factors have been reported to
play a role in the control ofBcl-x splicing. In normally growing 293
cells, the production of Bcl-xS is strongly repressed by hetero-
geneous nuclear ribonucleoprotein (hnRNP) K bound immedi-
ately upstream of the 50ss of Bcl-xS (Revil et al., 2009). In
contrast, hnRNP F/H proteins act as activators and are recruited
immediately downstream of the Bcl-xS 50ss (Garneau et al.,
2005). hnRNP F/H stimulate the 50ss of Bcl-xS possibly by pre-
venting the formation of inhibitory G-quadruplexes encompass-
ing the splice site (Dominguez et al., 2010). The binding of
RBM25 in exon 2 helps to recruit U1 snRNP to the Bcl-xS 50ss
(Zhou et al., 2008). Both RBM11 and PTBP1 enhance the pro-
duction of Bcl-xS by preventing the interaction of SRSF1 (Bielli
et al., 2014a; Pedrotti et al., 2012). SRSF1 and RBM10, respec-
tively, encourage and repress the production of Bcl-xL (Cloutier
et al., 2008; Moore et al., 2010; Paronetto et al., 2007). Core and
auxiliary components of the exon-junction complex were identi-
fied as repressors of the 50ss of Bcl-xS (Michelle et al., 2012).uthors.
commons.org/licenses/by/4.0/).
Recently, a long non-coding RNA (lncRNA) named INXS was
also implicated (DeOcesano-Pereira et al., 2014). INXS is
transcribed from the opposite genomic strand of Bcl-x and its
expression increases the production of Bcl-xS. Upregulation
of Sam68 in collaboration with hnRNP A1 promotes Bcl-xS
splicing, whereas the Fyn1 tyrosine kinase that targets Sam68
represses it (Paronetto et al., 2007). The transcription factor
FBI-1 interacts with Sam68 to reduce its binding to Bcl-x tran-
scripts and repress the production of Bcl-xS (Bielli et al., 2014b).
Although a signaling route involving protein kinase C (PKC) en-
forces the homeostatic repression of Bcl-xS splicing in 293 cells
(Revil et al., 2007), more than 20 signaling components affect
Bcl-x splicing in HeLa cells (Moore et al., 2010). Moreover, the
PP1 phosphatase is linked to Bcl-x splicing by acting on
SF3B1, which represses the production of Bcl-xS (Massiello
et al., 2006). Repression of Bcl-xS is lifted following DNA dam-
age. UV irradiation promotes the production of Bcl-xS through
an ATM-independent process that changes the speed of elonga-
tion of RNA polymerase II (Mun˜oz et al., 2009). UV exposure also
increases INXS expression (DeOcesano-Pereira et al., 2014).
The DNA intercalating anti-cancer drugs oxaliplatin and cisplatin
switch splicing in favor of Bcl-xS (Shkreta et al., 2008), and this
shift occurs through activation of the DNA damage-associated
ATM/CHK2 signaling axis (Shkreta et al., 2011).
Here, we document a role for the SR protein SRSF10 in modu-
lating the production of pro-apoptotic Bcl-xS transcripts. In nor-
mally growing 293 cells, decreasing and increasing the level of
SRSF10 respectively prevent and encourage the production
of Bcl-xS. When DNA damage is induced with oxaliplatin,
SRSF10 is critical to implement a splicing switch that increases
the level of Bcl-xS. Oxaliplatin promotes the dephosphorylation
of SRSF10 and prevents SRSF10 and hnRNP K from interacting
with the hnRNP F/H-bound Bcl-x pre-mRNA. The signaling
cascade induced by the DNA damage response therefore con-
verges on SRSF10, likely changing its interaction with hnRNP
proteins and the Bcl-x pre-mRNA to favor the production of a
pro-apoptotic regulator. We show that SRSF10 is required to
implement DNA damage-induced splicing shifts in other tran-
scripts encoding components involved in apoptosis, cell-cycle
control, and DNA repair, indicating that SRSF10 connects DNA
damagewith the alternative splicing of transcripts that determine
cell fate.
RESULTS
SRSF10 Controls Bcl-x Splicing
Bcl-x is alternatively spliced to produce two variants: the short
pro-apoptotic Bcl-xS and the longer anti-apoptotic Bcl-xL
(Figure 1A). As part of a screen to identify RNA binding pro-
teins that control Bcl-x splicing, we noted that the small inter-
fering RNA (siRNA)-mediated depletion of SRSF10 in 293 cells
decreased the relative level of transcripts encoding the pro-
apoptotic Bcl-xS variant. Although the impact of depleting
SRSF10 is statistically significant, the amplitude of the change
was relatively small (approximately 10 percentage points at the
highest concentration of siRNA) (Figure 1B). A similar decrease
was observedwhen the depletion of SRSF10was tested on tran-
scripts expressed from theBcl-xminigene X2 (Figure 1C). To testthe effect of increasing the level of SRSF10, we ectopically ex-
pressed a HA-tagged and a FLAG-tagged SRSF10 in 293 cells;
both versions stimulated the relative level of Bcl-xS transcripts
derived from the X2 minigene by nearly 30 percentage points
(Figure 1D).
SRSF10 contains one N-terminal RNA-recognition domain
(RRM) necessary and sufficient for sequence-specific RNA bind-
ing and two C-terminal arginine- and serine-rich domains (RS1
and RS2) involved in protein-protein interactions (Shin et al.,
2005). To investigate which domains are required for the activity
of SRSF10 on Bcl-x splicing, we produced a set of HA-SRSF10
variants lacking one or several domains (Figure 1E). Expression
of the variants was verified by immunoblotting with an anti-HA
antibody (Figure 1F). The activity of SRSF10 on Bcl-x splicing
was completely lost when the RRM or the RS1 domain was
deleted (Figure 1G). In contrast, deletion of the C-terminal end
of SRSF10 that contains the RS2 domain did not prevent activity.
Thus, the N-terminal portion of SRSF10 that contains the RRM1
and the RS1 domains is sufficient for modulating Bcl-x splicing.
SRSF10 Control of Bcl-x Splicing Requires hnRNP F/H
To assess whether SRSF10 acts through a defined sequence
element, we tested a set of Bcl-x minigenes carrying individual
deletions of previously identified regulatory elements flanking
the competing 50 splice sites (Figure 2A). As shown in Figure 2B,
the deletion of each element had the expected impact on Bcl-x
splicing. For all deletions, except that of B2 and B2G, HA-
SRSF10 stimulated the level of Bcl-xS to or near the maximal
amount produced from the wild-type Bcl-x construct, indicating
that B2G is the minimal element required for the SRSF10-
induced splicing shift. B2G is bound by the hnRNP F and H pro-
teins to enhance Bcl-xS splicing (Garneau et al., 2005). Notably,
the SRSF10-induced production of Bcl-xS was compromised by
the siRNA-mediated depletion of hnRNP F/H (Figure 2C; from an
average of 52 percentage points in the controls to an average of
28 percentage points in the siF/H-treated samples). The statisti-
cal significance of this difference (two-tailed t test with p value
of 0.012) indicates that hnRNP F/H proteins are important for
modulation of Bcl-x splicing by SRSF10.
As the RRM domain of SRSF10 is essential for activity (Fig-
ure 1G), SRSF10 may bind to the Bcl-x pre-mRNA. Consistent
with this view, antibodies against SRSF10 recovered the Bcl-x
pre-mRNA from a cell extract (see below). However, a gel-shift
assay did not detect a stable interaction between recombinant
SRSF10 and a 223-nt-long Bcl-x RNA that includes B2G (Fig-
ure S1A). Although GA-rich motifs that represent binding sites
for SRSF10 are absent in B2G, putative high-affinity binding sites
in the SB1 element (Figure S1B) are not required for the SRSF10-
induced splicing shift (Figure 2B). Thus, SRSF10 may interact
with other portions of the Bcl-x pre-mRNA, or its association
with the pre-mRNA may occur or be stabilized by interaction
with other RNA binding proteins.
Because the impact of SRSF10 on Bcl-x splicing requires
hnRNP F/H, SRSF10 may interact with hnRNP F/H. To test this
hypothesis, we performed an immunoprecipitation assay using
extracts from 293 cells expressing FLAG-SRSF10. Extracts
were pre-treated with ribonuclease A to eliminate interactions
that occur through RNA bridging. The immunoblot reveals thatCell Reports 17, 1990–2003, November 15, 2016 1991
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Figure 1. SRSF10 Controls the Alternative
Splicing of Bcl-x
(A) Schematic representation of the human Bcl-x
gene (BCL2L1) with relevant portions included in
minigene X2, and the positions of the RT primer
and PCR primer pairs used to carry RT-PCR
assays.
(B) Following RNAi in 293 cells with the indicated
concentrations of siSRSF10, an immunoblot with
anti-SRSF10 antibodies was carried out (top
panel). The positions of the full–length (SRSF10-1)
and truncated splice variant (SRSF10-2) are
shown. RT-PCR assays performed on the endog-
enous Bcl-x transcripts; the separation of radio-
labeled RT-PCR products is shown for one
experiment in the middle panel, with the positions
of the Bcl-xS and Bcl-xL products indicated. The
histograms shown in the bottom panel represent
the average production of Bcl-xS in percentage
from triplicates with SDs.
(C) Assay as in (B), except that 293 cells were
transfected with the Bcl-x minigene X2, and the
RT-PCR assay used a minigene-specific pair of
primers.
(D) Plasmids allowing expression of HA-SRSF10
and FLAG-SRSF10 were co-transfected with
minigene X2. The impact on Bcl-x splicing was
monitored as in (C). The CTRL sample was only
transfected with X2, whereas pCDNA3.1 is an
empty expression plasmid co-transfected with X2.
(E) Schematic representation of the HA-SRSF10
and derivatives lacking various domains.
(F) After transfection in 293 cells (quantity of
plasmid transfected indicated in micrograms),
the expression of HA-SRSF10 and derivatives was
verified by immunoblotting using anti-HA antibody.
(G) Samples of (F) were tested for Bcl-x splicing
using the X2 reporter as described in (D). Error
bars indicate SD. In all cases, asterisks represent
significant p values (two-tailed Student’s t test)
comparing the means between samples and
their respective controls; *p < 0.05, **p < 0.01, and
***p < 0.001.anti-hnRNP F and anti-hnRNP H antibodies recovered FLAG-
SRSF10 (Figure 2D), indicating that SRSF10 is physically associ-
ated with hnRNP F/H (estimated at 0.5%–1%of the total amount
of SRSF10, based on input level and recovery by immunoprecip-
itation). The reciprocal immunoprecipitation performed with anti-
FLAG recovered hnRNP F (Figure S2A). hnRNP F and H also
interact with endogenous SRSF10 (Figures S2B–S2D).1992 Cell Reports 17, 1990–2003, November 15, 2016hnRNP K interacts with element B1U
immediately upstream of the 50ss of
Bcl-xS to repress it in 293 cells (Fig-
ure 2A) (Revil et al., 2009). The depletion
of hnRNP K using RNAi increased the
production of Bcl-xS made from X2
(Figure 2E) and the endogenous Bcl-x
transcripts (Figure S2F) (Revil et al.,
2009). As a consequence, the amplitude
of the response to HA-SRSF10 was
reduced from 44 to 22 percentage pointswhen hnRNP K was partially depleted (p value of 0.04 using
a two-tailed t test) (Figure 2E). These results and the observa-
tion that HA-SRSF10 further stimulates the production of
Bcl-xS when hnRNP K is partially depleted may be explained
if SRSF10 helps relieve repression by hnRNP K, and that
it neutralizes the K proteins that remain after partial deple-
tion. Likewise, deleting B1U activates the 50ss of Bcl-xS, but
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Figure 2. SRSF10 Requires hnRNP F/H to
Control Bcl-x Splicing and Interacts with
hnRNP F, H, and K Proteins
(A) Schematic representation of regulatory elements
surrounding the 50 splice site of Bcl-xS.
(B) The X2 minigene and derivatives were trans-
fected either alone or with the HA-SRSF10 plasmid.
RT-PCR assays were carried out, and radiolabeled
RT-PCR products were fractionated on a non-
denaturing gel to quantitate Bcl-xS and Bcl-xL
products. The histograms represent the average
percentage of Bcl-xS products from triplicate
experiments.
(C) siF/H was used to deplete hnRNP F/H with an
immunoblot shown to verify depletion. HA-SRSF10
was transfected in 293 cells treated or not with siF/
H. RT-PCRwas carried out to detect theBcl-x splice
variants, as described in (B).
(D) Immunoprecipitation assays using 293 cells
transfected with FLAG-SRSF10. The material
recovered was fractionated and transferred on
nitrocellulose decorated with anti-FLAG antibodies.
(E) siK was used to deplete hnRNP K and an
immunoblot is shown. HA-SRSF10 was transfected
in 293 cells treated or not with siK. RT-PCR was
carried out to detect the Bcl-x splice products, as
described in (B).
(F) Immunoprecipitation assays with hnRNP K
antibody. Using 293 cells transfected with FLAG-
SRSF10, the recovered material was fractionated,
transferred on nitrocellulose that was decorated
with anti-FLAG antibodies. ‘‘xx’’ and ‘‘x’’ indicate
the large and small immunoglobulin subunits that
react with the secondary antibody, respectively.
Error bars indicate SD. Asterisks represent p values
(two-tailed Student’s t test) comparing the means
between samples and their respective controls;
*p < 0.05, **p < 0.01, and ***p < 0.001.HA-SRSF10 offered weak but significant stimulation (Figure 2B),
possibly because it antagonizes the impact of a hnRNP K
binding site in the B1D region (Revil et al., 2009). A physical
interaction between SRSF10 and hnRNP K is supported by
the observation that an immunoprecipitation assay using anti-
hnRNP K antibodies and an RNase-treated extract recovered
FLAG-SRSF10 (Figure 2F). Based on input and recovery levels,
0.7% of FLAG-SRSF10 is estimated to be in interaction with
hnRNP K. This interaction with hnRNP K also occurs with
endogenous SRSF10 (Figures S2C, S2D, and S2E). Thus, over-
expression of HA-SRSF10 relieves the repression conferred by
hnRNP K, and this effect may occur through a direct interaction
of SRSF10 with hnRNP K and hnRNP F/H.Cell ReporDNA Damage Alters the Interaction
of SRSF10 with Splicing Regulators
and the Bcl-x Pre-mRNA
Repression in the production of pro-
apoptotic Bcl-xS is lifted when a genotoxic
stress is applied to 293 cells. For example,
oxaliplatin shifts splicing to Bcl-xS by acti-
vating the DNA damage response (DDR)
pathway (Shkreta et al., 2011). The 361-ntregulatory region SB1, located 150 nt upstream of the Bcl-xS
50ss (Figure 2A), like the B1U element bound by hnRNP K, is
required for repression of the 50ss of Bcl-xS (Revil et al., 2007;
Shkreta et al., 2011); when either the B1U element or the SB1 re-
gion is removed, oxaliplatin fails to further stimulate Bcl-xS
splicing (Figure 3A). To achieve its function, SB1 may communi-
cate with regulators bound close to the Bcl-xS 50ss. Consistent
with this view, the B2G element, which is required for the activity
of hnRNP F/H and SRSF10, is essential for the oxaliplatin-
mediated splicing switch (Figure 3A). Likewise, the oxaliplatin-
induced splicing switch is compromised when the level of either
hnRNP F/H or SRSF10 is reduced by RNAi (Figures 3B and 3C).
In the case of hnRNP F/H, the oxaliplatin shift decreases 3-foldts 17, 1990–2003, November 15, 2016 1993
from an average of 43 to an average of 13 percentage points (p
value < 0.0001 by two-tailed t test), whereas in the case of
SRSF10, the oxaliplatin shift decreases 2.5-fold from an average
of 31 to an average of 13 percentage points (p value < 0.0001 by
two-tailed t test). Thus, hnRNP F/H and SRSF10 contribute to
enforce the use of the 50ss of Bcl-xS when the DDR pathway is
activated by oxaliplatin.
Given that SRSF10 interacts with hnRNP F/H and hnRNP K,
we asked whether oxaliplatin affects these interactions. First,
we observed that oxaliplatin does not change the expression
level of SRSF10, hnRNP F, and hnRNP K (Figures S3A and
S3B). Likewise, the depletion of SRSF10 did not affect the
expression of hnRNP F and K, nor did the depletion of hnRNP
F/H or K greatly affect the expression of SRSF10 (Figures S3C
and S3D). Second, we performed immunoprecipitation assays
with anti-F, anti-H, and anti-K antibodies. The results indicate
that the interaction between SRSF10 and hnRNP K is main-
tained when cells are treated with oxaliplatin (Figure 3D). In
contrast, the interaction between SRSF10 and hnRNP F and
H was nearly completely lost in oxaliplatin-treated cells (Fig-
ure 3D). To identify RS domains of SRSF10 that contribute to
the interaction with hnRNP F/H, and whose ability to interact
may be altered by oxaliplatin, we used FLAG-RS1 and RS2 de-
rivatives (Figure 3E). Notably, the RS1 but not the RS2 domain
of SRSF10 interacts with hnRNP F/H, and the interaction of
RS1 with both hnRNP F and hnRNP H was sensitive to oxalipla-
tin (Figure 3E). In contrast, hnRNP K interacts with both RS do-
mains, and these interactions are not disrupted by oxaliplatin
(Figure 3E). These results suggest that the RS1 domain con-
tains residues that contribute to the dynamic interaction of
SRSF10 with hnRNP F/H.
To address whether oxaliplatin also affects the interaction of
each of the above factors with the Bcl-x pre-mRNA, we used
qRT-PCR to measure the amount of Bcl-x RNA recovered by
immunoprecipitation with antibodies against hnRNP F, H, K,
and FLAG. The reverse transcriptase primer and one PCR primer
were designed to map in the intron downstream of the Bcl-xL
50ss to ensure that interactions with the pre-mRNA rather than
the mRNA were monitored (Figure 3F; Table S1). The recovered
material was treated with DNase I to eliminate a potential contri-
bution of contaminating genomic DNA. As shown in Figure 3F
and Table S1, oxaliplatin decreased the association of SRSF10
and hnRNP K with the Bcl-x pre-mRNA, but increased the inter-
action of hnRNP F and H.
We propose the following model to explain the results of
the overexpression, depletion, and immunoprecipitation assays.
In normal growth conditions, hnRNP K represses the 50ss of Bcl-
xS on amajority of transcripts (Figure 4A). Themechanism of this
repression is not known, but hnRNP K may antagonize the bind-
ing of hnRNP F/H that is required to make the 50ss of Bcl-xS
structurally available (Dominguez et al., 2010; Garneau et al.,
2005). By associating with hnRNP K on a small fraction of tran-
scripts, SRSF10 may neutralize repression by encouraging the
recruitment of hnRNP F/H to promote 50ss recognition (Fig-
ure 4B). In normally growing 293 cells, the impact of depleting
SRSF10 or hnRNP F/H is small because the 50ss of Bcl-xS
on most transcripts is repressed by hnRNP K (Figure 4A). Oxali-
platin reduces the binding of hnRNP K and SRSF10 to the Bcl-x1994 Cell Reports 17, 1990–2003, November 15, 2016pre-mRNA, and although the association of SRSF10 with hnRNP
K is maintained, the interaction of SRSF10 with hnRNP F/H is
disrupted. This reconfiguration may be important to keep hnRNP
K from being recruited to the pre-mRNA and would explain why
the production of Bcl-xS is compromised when SRSF10 is
depleted in oxaliplatin-treated cells. The reduced recruitment
of hnRNP K would facilitate hnRNP F/H binding and stimulate
splicing to the 50ss of Bcl-xS (Figure 4C).
Oxaliplatin Affects the Phosphorylation of SRSF10 and
hnRNP K
Given that oxaliplatin activates DDR signaling (Shkreta et al.,
2011), and that phosphorylation controls the activity of
SRSF10 (Shin et al., 2004, 2005; Shin and Manley, 2002), we
hypothesized that oxaliplatin may affect the phosphorylation
of SRSF10. The immunoblot performed to evaluate the expres-
sion of SRSF10 following oxaliplatin treatment showed the
presence of faster migrating forms that are consistent with
dephosphorylation (Figure S3B). We repeated this gel fraction-
ation after treating a cell extract with calf intestinal phosphatase
(CIP), which converts endogenous SRSF10 into faster gel-
migrating forms (Figure 5A), matching previous observations
(Shi and Manley, 2007). Treating 293 cells with oxaliplatin also
converted endogenous SRSF10 into faster migrating forms
(Figure 5A). To identify peptides in SRSF10 that become de-
phosphorylated when cells are treated with oxaliplatin, we per-
formed an anti-FLAG immunoprecipitation in duplicate using
cells expressing FLAG-SRSF10, and subjected the recovered
material to liquid chromatography-tandem mass spectrometry
(LC-MS/MS) analysis after trypsin digestion. SRSF10 peptides
covered approximately 40% of the protein (Figure 5B). Of
these, peptide SFDYNYR carries a serine at position 133
(RS1 domain) that was phosphorylated in 40% of all the
SFDYNYR peptide recovered in untreated samples (in bold in
Figure 5B). The relative recovery of the phosphorylated version
of this peptide was reduced 2-fold in samples derived from
cells treated with oxaliplatin (Figure 5C). In contrast, the relative
level of a different peptide carrying a phosphorylated serine
mapping in the RRM domain of SRSF10 was not significantly
affected by oxaliplatin (Figure 5C). Thus, oxaliplatin promotes
the dephosphorylation of FLAG-SRSF10 at serine 133.
Based on the gel migration profile of SRSF10 from oxaliplatin-
treated cells (Figure 5A), other dephosphorylation events likely
contribute to the strong effect of oxaliplatin on the migration of
SRSF10. Given that our peptide coverage underrepresents the
RS1 and RS2 domains (Figure 5B), our assessment of the phos-
phorylation status of SRSF10 is likely to be incomplete. Never-
theless, we assessed the functional contribution of serine 133
by producing a deletion variant (HA-DS133; Figure 5D). Given
the presence of another serine at position 131, we also mutated
this position individually and in combination with serine 133 (HA-
DS131 and HA-DS131-DS133; Figure 5D). When cotransfected
in 293 cells with the Bcl-x minigene, HA-DS131 and HA-DS133
displayed a reduced capacity at stimulating the production
of Bcl-xS, whereas the double deletion had a stronger effect
(Figure 5E). HA-DS131-DS133 had a similar impact on endoge-
nous Bcl-x transcripts (Figure S4). Changing S131 and S133 to
alanines also compromised activity but not replacing them with
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Figure 3. The Bcl-x Splicing Shift Induced by Oxaliplatin Requires SRSF10 and hnRNP F/H, and Is Associated with the Loss of Interaction
between SRSF10 and hnRNP F/H
(A) The X2 minigene and derivatives lacking different elements were transfected into 293 cells. Four hours later, cells were treated with oxaliplatin for 24 hr. The
impact of oxaliplatin on Bcl-x splicing was determined by RT-PCR.
(B) The role of hnRNP F/Hwas tested by depleting hnRNP F/H byRNAi. The top panel shows an immunoblot for hnRNP F. Themiddle and bottom panels show the
results of the RT-PCR assays to detect endogenous Bcl-x transcripts.
(legend continued on next page)
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Figure 4. Schematic Model of the Proposed
Role of SRSF10, hnRNP F/H, and hnRNPK in
Bcl-x Pre-mRNA Splicing, and How Oxali-
platin Reprograms Their Interactions
(A) Repressor complex representing the major
regulatory assembly in normally growing 293 cells.
(B) Activating complex proposed to form on a
minor fraction of Bcl-x transcripts in normally
growing 293 cells or when SRSF10 is overex-
pressed.
(C) Impact of oxaliplatin on the interaction of reg-
ulatory components leading to the activation of the
50ss of Bcl-xS.the phosphomimetic aspartate (Figure S4). However, having
aspartate at these two positions did not compromise the impact
of oxaliplatin (data not shown), possibly indicating that addi-
tional dephosphorylated residues make important contributions.
Because oxaliplatin affects the phosphorylation of SRSF10 in a
domain (RS1) that is important for its activity and its interaction
with other splicing regulators, we tested the impact of deleting
both S131 and S133 on the ability of RS1 to interact with hnRNP
proteins. Strikingly, the mutations strongly compromised the
ability of RS1 to interact with hnRNP F and hnRNPH, and slightly
reduced the interaction with hnRNP K (Figure 5F).
hnRNP K displays a reduced ability to bind to the Bcl-x pre-
mRNA when cells are treated with oxaliplatin (Figure 3F).
Because the interaction of hnRNP K with phosphatase 2A inhib-
itor protein SET increases the nucleic acid binding of hnRNP K
(Almeida et al., 2014), dephosphorylation of hnRNP K may
reduce its binding to the Bcl-x pre-mRNA. To determine whether
oxaliplatin affects the phosphorylation of hnRNP K, we recov-
ered endogenous hnRNPK in cells treated or not with oxaliplatin,
and subjected the recovered material to LC-MS/MS analysis
after trypsin digestion. We identified one phosphorylated pep-
tide specific to hnRNP K, and its recovery relative to the non-
phosphorylated version was reduced 2-fold in cells treated
with oxaliplatin (Figure S5). This peptide contains a phosphoser-
ine at position 216 that maps in between the KH2 and RGG do-
mains. Because phosphorylation of serine 216 contributes to the
transcriptional activity of hnRNP K, its dephosphorylation may
also decrease binding to the Bcl-x pre-mRNA.(C) The role of SRSF10 on the oxaliplatin-induced Bcl-x splicing shift was tested
middle and bottom panels show the results of the RT-PCR assays on endogeno
(D) Immunoprecipitation of FLAG-SRSF10 was performed with anti-hnRNP F, H
aliplatin, and expressing or not FLAG-SRSF10. The input content of FLAG-SRSF1
Immunoprecipitates were fractionated on gel and proteins were transferred to
immunoglobulin subunit used for the immunoprecipitation that reacts with the se
(E) The immunoprecipitation assays used cells expressing SRSF10-FLAG, RS1
described in (D). Anti-K antibodies are from mouse, whereas anti-F and anti-H a
cipitation. ‘‘xx’’ and ‘‘x’’ indicate the large and small immunoglobulin subunits th
(F) Immunoprecipitation was carried out on cells treated or not with oxaliplatin. Th
the top. Raw data are provided in Table S1. The differential between values obt
tograms. The result obtainedwith IgG control immunoprecipitations is provided in
comparing immunoprecipitations performed with cells treated with formaldehyde
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Splicing of Transcripts Implicated in the DDR
The activity of splicing regulatory factors is often altered by DNA
damage possibly to coordinate the splicing regulation of genes
involved in cell-cycle control, DNA repair, and apoptosis
(Shkreta and Chabot, 2015). To determine whether SRSF10 reg-
ulates splicing of other transcripts encoding proteins implicated
in the DDR, we tested genes involved in apoptosis, cell-cycle
control, and DNA repair, and identified 28 events whose alterna-
tive splicing was sensitive to oxaliplatin (Dpercent splicing index
[DPSI] R 5 percentage points with p values < 0.05; Table S2;
CTRL–OXALI column). Of these, 13 had their oxaliplatin-medi-
ated shift partially abrogated by the depletion of SRSF10 (Table
S2; OXALI–OXALIsi column). In addition to Bcl-x, seven units had
significantly smaller amplitude in the oxaliplatin-induced shift
when SRSF10 was depleted (Figure 6). For example, oxaliplatin
reduced the skipping of exons 9–10 in BRCA1 by 24 percentage
points but only by 13 percentage points when SRSF10 was
depleted (Figure 6B; p value of 0.0027 using two-tailed t test).
Statistically significant differences were also obtained for units
in CHEK2, MLH3, RBBP8, PCBP4, TNFRSF10B, and CASP8
(Figure 6; Table S2). In contrast, of the 43 units that did not
respond to oxaliplatin, only BCLAF1 and AKIP1 were regulated
by SRSF10 (Table S3), suggesting that SRSF10 preferentially
controls units that respond to DNA damage. Interestingly and
in contrast to Bcl-x, the association of FLAG-SRSF10 with the
BCLAF1 and AKIP1 pre-mRNAs was not affected by oxaliplatin
(Table S4), indicating that the oxaliplatin-mediated drop in theby depleting siSRSF10. The top panel confirms the depletion of SRSF10. The
us Bcl-x transcripts.
, and K antibodies using extracts prepared from cells treated or not with ox-
0 is shown and represents 1/50th of the samples used for immunoprecipitation.
nitrocellulose decorated with anti-FLAG antibodies. ‘‘xx’’ indicates the large
condary antibody.
-FLAG, or the RS2-FLAG treated or not with oxaliplatin. The procedure is as
ntibodies are from rabbit. A rabbit IgG was used for the control immunopre-
at react with the secondary anti-mouse antibody, respectively.
e recovered RNA was quantitated for Bcl-x pre-mRNA using primers shown on
ained for each antibody comparing the impact of oxaliplatin is plotted in his-
Table S1. Also shown in Table S1 are the results obtained from two experiments
and untreated cells.
A B
C D
E F
Figure 5. Dephosphorylation of SRSF10 by Oxaliplatin
(A) Total cellular extracts were collected 24 hr after treatment or not with oxaliplatin. Aliquots of the untreated cellular extract were incubated with or without calf
intestinal phosphatase (CIP) for 15 min at 37C. Proteins were fractionated on gel and transferred to nitrocellulose to reveal SRSF10.
(B) Amino acid sequence of the SRSF10-1 protein showing the different domains (RRM, RS1, and RS2) in differently shaded boxes. The regions of SRSF10 to
which peptides identified by LC-MS/MS analysis mapped are underlined.
(C) Proteins recovered from duplicate anti-FLAG immunoprecipitations using cells expressing FLAG-SRSF10 and treated or not with oxaliplatin were analyzed by
LC-MS/MS analysis after trypsin digestion. Histograms depict the relative abundance of two SRSF10 peptides containing a phosphorylated serine compared to
the respective unmodified versions. The peptide in the RS1 domain is shown in bold in (B), and the position of both serines is indicated.
(legend continued on next page)
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association of SRSF10with theBcl-x pre-mRNAdid not occur on
non-oxaliplatin-responsive transcripts.
Notably, for 10 of the 13 units sensitive to oxaliplatin that react
to a depletion of SRSF10, the impact of this depletion was more
important in oxaliplatin-treated cells than in control cells (i.e.,
DPSI between 6 and 17 percentage points in [OXALI–OXALIsi]
relative to DPSI of 2 to 7 percentage points in [CTRL–CTRLsi]
(Table S2; Figure 6). Thus, for seven alternative splicing units
and Bcl-x, the regulatory impact of SRSF10 becomes more
important when cells are treated with oxaliplatin.
Several units sensitive to both oxaliplatin and the depletion of
SRSF10 reside in genes encoding components involved in
apoptosis, DNA repair, and cell-cycle control, and hence are
associated with the DNA damage response. Oxaliplatin stimu-
lated the production of a BRCA1 variant lacking exons 9 and
10 (Figure 6B) that encode a linker region separating the RING
domain from the multiple protein interaction platform. RBBP8
encodes an endonuclease that controls cell-cycle G2/M
checkpoints and that interacts with BRCA1 to regulate the acti-
vation of CHK1. It is not known whether the splice variants of
RBBP8 display different activities. The intron retention event in
TNFRSF10B promoted by oxaliplatin adds a 29-amino acid
segment whose functional impact is not known, as is the case
for the CASP8 variants. The checkpoint kinase CHK2 is normally
activated upon DNA damage to induce cell-cycle arrest (Mat-
suoka et al., 1998), and oxaliplatin promotes the inclusion of an
exon in CHEK2 that would produce a truncated version through
frameshift. The fact that SRSF10 is required for the DNA-dam-
age-induced shifts in CHEK2 suggests that SRSF10 may
help override cell-cycle checkpoints. In combination with the
increased production of pro-apoptotic Bcl-xS, the net effect
may accelerate commitment toward apoptosis. Although the
precise function of many of the above splice variants in our cell
system remains to be assessed, a recent analysis in chicken
DT-40 cells suggested a role for SRSF10 in controlling the
splicing of transcripts of genes that belong to these functional
categories; alternative splicing of Bap1 (BRCA1-associated pro-
tein), Cdk13 and Casp1 were in the top 12 events controlled by
SRSF10 (Zhou et al., 2014b). Likewise, transcripts that code
for proteins linked to apoptosis (e.g., BCLAF1 and RAC1) form
a top functional category controlled by SRSF10 in human RKO
cells (Zhou et al., 2014a). Inspecting the sequence of SRSF10-
regulated exons and their flanking introns for the presence of
GA-motifs did not reveal an over-representation of putative
SRSF10 binding sites relative to randomly selected alternative
splicing units that do not respond to a depletion of SRSF10 (Fig-
ure S6). To determine whether the SRSF10-dependent response
to oxaliplatin may implicate regulators that interact with SRSF10
to control Bcl-x splicing, we tested whether hnRNP F/H and
hnRNP K were also contributing to regulation. Notably, all units,
except RBBP8, were regulated by hnRNP F/H, and two units(D) Diagram of the mutated versions of HA-SRSF10 carrying either a deletion of
(E) The impact of mutated HA-SRSF10 onBcl-x splicing was tested by co-transfec
represented in histograms with asterisks indicating p values when samples are co
and ***p < 0.001.
(F) The anti-F, anti-H, and anti-K immunoprecipitations used extracts from cells
procedure is as described in Figure 3E. A rabbit IgG was used in the control imm
1998 Cell Reports 17, 1990–2003, November 15, 2016(RBBP8, PCBP4) were controlled by hnRNP K (Figure S7).
Depleting hnRNP F/H altered the response to oxaliplatin for
three units (BRCA1, CHEK2, and TNFRSF10B). This result
suggests that coordination of oxaliplatin-induced splicing shifts
often implicate the combinatorial contribution of SRSF10,
hnRNP F/H, and hnRNP K.
DISCUSSION
We have documented a role for SRSF10 in Bcl-x splicing. In
normally growing 293 cells, only small amounts of the pro-
apoptotic Bcl-xS splice variant are made. The overexpression
of SRSF10 encourages the production of Bcl-xS, but this effect
is prevented when hnRNP F/H are depleted or when the
sequence to which they bind, immediately downstream of the
50ss of Bcl-xS, is removed. Because SRSF10 interacts with
hnRNP F/H and the repressor protein hnRNP K, our results sug-
gest that SRSF10, hnRNP F/H, and hnRNP K are part of a com-
plex that attenuates repression of the 50ss of Bcl-xS (Figure 4B).
hnRNP K-mediated repression likely occurs on the bulk of Bcl-x
pre-mRNAs (Figure 4A), whereas the SRSF10-mediated anti-
repression may be effective only on a small fraction of Bcl-x
transcripts.
Treating 293 cells with oxaliplatin elicits a large increase in the
production of pro-apoptotic Bcl-xS, and both SRSF10 and
hnRNP F/H are required for this splicing shift to occur. Oxaliplatin
abrogates the interaction of SRSF10with hnRNP F/H, and leaves
the SRSF10/hnRNP K interaction unaffected. Moreover, oxali-
platin decreases the association of both SRSF10 and hnRNP K
with the Bcl-x pre-mRNA, but increases that of hnRNP F/H.
These results suggest that oxaliplatin prevents the association
of a SRSF10/hnRNP K complex with the Bcl-x pre-mRNA, allow-
ing hnRNP F/H to bind to Bcl-x transcripts and enforce the pro-
duction of Bcl-xS. Because hnRNP F helps maintain the G-rich
environment of the Bcl-xS 50ss in a single-stranded conforma-
tion (Dominguez et al., 2010), hnRNP F/H may facilitate U1
snRNP binding to this splice site. Consistent with the view
that the DDR activates a cascade of signaling events often
converging on splicing regulators (Dutertre et al., 2014; Shkreta
and Chabot, 2015), we identified a phosphoserine in hnRNP K
that becomes dephosphorylated when cells are treated with ox-
aliplatin. Although the impact of this modification remains to be
evaluated, the interaction of hnRNP K with the phosphatase in-
hibitor protein SET increases its binding to ssDNA (Almeida
et al., 2014), in line with the notion that the dephosphorylation
of hnRNP K may reduce RNA binding. Our mass spectrometry
analysis also identified a phosphoserine (Ser133) in SRSF10
that becomes dephosphorylated when cells are treated with ox-
aliplatin. Ser133 is located in the RS1 domain of SRSF10. RS1 is
essential for the activity of SRSF10, and by itself can interact with
hnRNP F/H and hnRNP K, and mimic the oxaliplatin-mediatedS131, S133, or both.
ting minigene X2 and carrying out RT-PCR assays. The percentage of Bcl-xS is
mpared to wild-type HA-SRSF10. Error bars indicate SD. *p < 0.05, **p < 0.01,
expressing RS1-FLAG or RS1-DD-FLAG (structure diagrammed on top). The
unoprecipitation.
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Figure 6. Impact of the Depletion of SRSF10
on the Oxaliplatin-Induced Splicing Shifts
(A) Immunoblot showing the siRNA-mediated
depletion of SRSF10 in cells treated or not with
oxaliplatin.
(B–H) For each subsequent panel, the name of the
gene and the structure of its relevant portion are
shown. (B) BRCA1. Exon numbers are shown. (C)
CHEK2. Size of exons in nucleotides. (D)MLH3. Size
of exons in nucleotides. (E) RBBP8. Size of exons in
nucleotides. (F) PCBP4. Size of exons in nucleo-
tides. (G) TNFRSF10B. Size of exons in nucleotides.
(H) CASP8. Size of exons in nucleotides. In each
panel, the RT-PCR analysis presents electrophero-
grams with molecular weight markers. Triplicate
experiments are shown as histograms with percent
splicing index (PSI). Error bars indicate SD. Aster-
isks indicate significant P values obtained when
comparing control with siSRSF10 or samples
treated with oxaliplatin with samples treated with
both siSRSF10 and oxaliplatin; *p < 0.05, **p < 0.01,
and ***p < 0.001.changes in these interactions sustained by SRSF10. Deleting
Ser133 and the nearby Ser131, or substituting them for alanines,
reduced the ability of SRSF10 to control Bcl-x splicing. More-
over, the deletion of both Ser131 and Ser133 strongly decreased
the ability of the RS1 domain to interact with hnRNP F/H. The
above dephosphorylation events associated with the activity ofSR
cis
m
SR
ev
imCell Reporoxaliplatin fit well with our previous obser-
vation that phosphatases contribute to the
action of oxaliplatin on Bcl-x splicing
(Shkreta et al., 2011). Although we have
not demonstrated that the dephosphoryla-
tion of SRSF10 directly contributes to the
Bcl-x splicing shift, overall, our results are
consistent with a model whereby DNA
damage triggers the dephosphorylation
of SRSF10 and hnRNP K to reduce their
interaction with the Bcl-x pre-mRNA and
the hnRNP F/H proteins, allowing the latter
to stimulate the 50ss of Bcl-xS (Figure 4).
Under normal growth conditions, multi-
ple signaling routes converge on Bcl-x
splicing (Moore et al., 2010; Revil et al.,
2007). Ser133 in the RS1 domain of
SRSF10 is part of an environment that
matches the consensus phosphorylation
sites of several kinases, including PKC,
which is implicated in the homeostatic
regulation of Bcl-x splicing in 293 cells (Re-
vil et al., 2007). Upon DNA damage, these
signaling routes may be altered and new
ones may become activated. Previously,
we showed that oxaliplatin affects Bcl-x
splicing through ATM/CHK2 signaling and
the activation of phosphatases (Shkreta
et al., 2011). The oxaliplatin-mediated
inhibition of kinases that phosphorylateSF10, such as SRPK1 and SRPK2, is unlikely because
platin activates SRPK1/2 (Edmond et al., 2011). Oxaliplatin
ay promote the dissociation of 14-3-3 proteins, which protect
SF10 from dephosphorylation (Shi and Manley, 2007). How-
er, the RS2 domain of SRSF10, which contains residues
portant for the interaction with 14-3-3 proteins (Shi andts 17, 1990–2003, November 15, 2016 1999
Manley, 2007), is not required for modulation of Bcl-x splicing.
Thus, the precise signaling route affected by oxaliplatin that
leads to altered SRSF10 and hnRNP K function remains to be
identified. Moreover, it is unclear whether this signaling route is
operative in other cell lines. Although oxaliplatin shifts Bcl-x
splicing in all cancer cell lines tested so far (Shkreta et al.,
2008), as PKC signaling does not contribute to Bcl-x splicing
control in the cancer cell lines that we have tested (Revil et al.,
2007), it will be worth exploring whether the signaling network
that controls SRSF10 phosphorylation also operates in cancer
cell lines.
We cannot rule out that oxaliplatin affects the activity of other
factors controlling Bcl-x splicing. SRSF2 stimulates the produc-
tion of Bcl-xS (Merdzhanova et al., 2008) in H358 and A459 cells,
and cisplatin increases the activity of SRSF2 (Edmond et al.,
2011). In HeLa and 293 cells, however, the RNAi-mediated
knockdown of SRSF2 does not significantly affect Bcl-x splicing
(Papasaikas et al., 2015) (data not shown). Because SRSF1 stim-
ulates the 50ss of Bcl-xL (Cloutier et al., 2008; Paronetto et al.,
2007), its repression would increase Bcl-xS. However, UV and
cisplatin increase the activity of SRSF1 in MCF-7 and HeLa cells,
respectively (Comiskey et al., 2015). Whereas Sam68 collabo-
rates with hnRNP A1 to favor the production of Bcl-xS in
HEK293 cells (Paronetto et al., 2007), the topoisomerase inhibi-
tor methoxantone and UV provoke the accumulation of Sam68 in
nuclear granules and the retention of hnRNP A1 in the cyto-
plasm, respectively (Busa` et al., 2010; van der Houven van Oordt
et al., 2000). If oxaliplatin similarly changes the localization of
Sam68 and hnRNP A1, Bcl-xS production should decrease, in
contrast to what we observed. Finally, although UV slows RNA
polymerase II elongation to promote the production of Bcl-xS,
this pathway is independent of ATM/ATR and is not used when
cells are treated with doxorubicin (Mun˜oz et al., 2009). The
impact of oxaliplatin on transcription elongation remains to be
evaluated.
Our results therefore provide a detailed description of how
the DDR interfaces with regulatory factors to control alternative
splicing decisions on a gene that determines cell fate. The
modulation of protein-protein and protein-RNA interactions by
DNA damage has so far been documented only for the splicing
regulator EWS; UV promotes a relocalization of EWS associ-
ated with a reduction in its interaction with target transcripts,
whereas camptothecin and cisplatin disrupt the interaction of
EWS with YB-1 to affect transcription-coupled Mdm2 splicing
(Dutertre et al., 2010; Paronetto et al., 2011). The recent demon-
stration of the existence of large splicing regulatory complexes
containing RBFOX proteins and other regulatory hnRNP pro-
teins such as hnRNP H and M proteins (Damianov et al.,
2016) is consistent with the multiple interactions between
splicing regulators that were uncovered in our study. Whether
the composition of these complexes is systematically reconfig-
ured by various stresses is an intriguing question that remains to
be assessed.
SRSF10 Modulates the Splicing Response to DNA
Damage
The DDR activates a signaling network that coordinates DNA
repair with the cell cycle, and with apoptosis when damage is2000 Cell Reports 17, 1990–2003, November 15, 2016too extensive. Although many elements of this response
operate rapidly by post-translationally modifying components
of these machineries, a slower route implements regula-
tory changes in transcription and translation. DDR-mediated
changes in splice site selection is increasingly recognized as
another important path that controls the activity of machineries
that sense, repair, and react to DNA damage (Dutertre et al.,
2014; Naro et al., 2015; Shkreta and Chabot, 2015). Genotoxic
agents or treatments have a broad impact on the splicing and
alternative splicing of transcripts encoding proteins involved
in DNA repair, cell-cycle control, and apoptosis (reviewed in
the study by Shkreta and Chabot, 2015). However, the splicing
regulatory mechanisms affected by the DDR are less well
understood. UV, cisplatin, and the topoisomerase II inhibitor
etoposide increase the expression or phosphorylation of SR
proteins and modulate the alternative splicing of target tran-
scripts (Comiskey et al., 2015; Edmond et al., 2011; Leva
et al., 2012). UV also alters the level of phosphorylation of
RNA polymerase II to affect the speed of transcription and
splice site selection (Mun˜oz et al., 2009). In one recent example,
etoposide was shown to promote the phosphorylation of chro-
matin-bound BRCA1 to recruit spliceosomal proteins and stim-
ulate splicing of transcripts from the DNA repair genes ATRIP,
BACH, and EXO1 (Savage et al., 2014). In many cases, geno-
toxic stresses change the localization of splicing regulatory fac-
tors (Shkreta and Chabot, 2015). For example, DNA damage
partially relocalizes EWS to the nucleoli (Paronetto et al.,
2011), affecting alternative splicing in the same direction as a
depletion of EWS (Dutertre et al., 2010; Paronetto et al.,
2011). This situation may also be true for RBMX, FUS, SKIP,
and Tra2, whose individual depletions, like that of EWS, in-
crease DNA damage-induced apoptosis (Adamson et al.,
2012; Best et al., 2014; Chen et al., 2011; Dutertre et al.,
2010; Li et al., 2007; Paronetto et al., 2011).
Here, we have uncovered a mechanism by which DNA dam-
age controls alternative splicing of transcripts encoding pro-
teins involved in apoptosis, cell-cycle control, and DNA repair.
Although depletion of SRSF10 compromised several oxalipla-
tin-induced splicing shifts, depleting SRSF10 by itself only had
a modest or no impact on the splicing of these transcripts, sug-
gesting that SRSF10 is co-opted by the DDR to control a broad
set of splicing decisions. Based on our analysis of the role of
SRSF10 in Bcl-x splicing, its transformation into a more efficient
splicing regulator is associated with dephosphorylation, a pro-
cess that maintains its interaction with hnRNP K but decreases
its interaction with hnRNP F/H and with the Bcl-x pre-mRNA.
This regulatory strategy may similarly be applied to the control
of other SRSF10-dependent splicing units that respond to
oxaliplatin because hnRNP K and hnRNP F/H were implicated
in the splicing control of three and eight alternative splicing units
(out of nine tested), respectively. Although SRSF10was originally
described as a general splicing repressor activated by dephos-
phorylation, phosphorylated SRSF10 can also function as a
splicing activator (Feng et al., 2008; Shin and Manley, 2002).
Our results suggest that the modulating properties of SRSF10
may vary according to the splicing events that are interrogated.
Consistent with this view, SRSF10 controls the alternative
splicing of exon 5a in BCLAF1 in a variety of cancer cell lines
(Zhou et al., 2014a). The fact that this BCLAF1 splicing event is
not affected by oxaliplatin (Figure S8) suggests that SRSF10 op-
erates through different molecular mechanisms. Thus, SRSF10
controls a complex functional network because it suppresses
splicing during heat shock and M phase (Shin et al., 2004; Shin
and Manley, 2002), controls alternative splicing decisions that
elicit myoblast differentiation and glucose production, alters
the oncogenic properties of cancer cells (Wei et al., 2015;
Zhou et al., 2014a), and modulates the production of splice var-
iants implicated in apoptosis, cell-cycle control, and DNA repair
as part of the cellular response to DNA damage.
EXPERIMENTAL PROCEDURES
Plasmid Construction, Transfection
Plasmids expressing Bcl-x reporter mini-genes and 3XFLAG-SRSF10, FLAG-
SRSF10, and HA-SRSF10 were previously described (Cloutier et al., 2008; Gar-
neau et al., 2005; Revil et al., 2009; Shi and Manley, 2007; Shkreta et al., 2011).
Plasmids expressing SRSF10 andmutantswere produced byPCR site-directed
mutagenesis. pcDNA3.1-HA-SRSF10 or p3XFLAG-V14-SRSF10 were used as
PCR templates for Pfu-Turbo polymerase and respective primers listed in Table
S5. Products were cleaved with BamHI and EcoRI and inserted into pCDNA3.1-
HA, or with BglII and EcoRV and inserted into p3XFLAG-V14. Transfections
were carried out with polyethyleneimide (Polysciences) or Lipofectamine 2000
(Invitrogen).
RNAi Assays
Knockdown of SRSF10 was performed with the siGENOME SMARTpool-Hu-
man SRSF10 (2914-02-0005; Dharmacon). The siRNAs against hnRNP F/H
(GAACUGAACAAUUUCUUCC) and hnRNP K (UGAUACUCAAUAUGCGCUC)
were from previously published work (Garneau et al., 2005; Revil et al., 2009)
and synthesized by IDT. siRNAs were transfected (100 nM) using Lipo-
fectamine 2000 (Invitrogen). Proteins or RNA were extracted 72 hr post-
transfection.
Cell Culture and Drugs
Human 293 cells (EcR-293; Invitrogen) were grown at 37C (5%CO2) in DMEM
supplemented with 10% fetal bovine serum (FBS). Oxaliplatin was obtained
from the Centre de Chimiothe´rapie-CHUS.
Immunoblot Analysis
Whole-cell extracts were prepared by lysing cells in Laemmli sample buffer.
Equal amounts of total protein were fractionated on SDS-PAGE, and stan-
dard protocols were applied for western blotting. Proteins were revealed
with primary antibodies against HA-tag (Roche; 12CA5), FLAG (Sigma;
F3165), SRSF10 (Abcam; ab77209), hnRNP F or hnRNP H (kindly provided
by Doug Black), hnRNP K (kindly provided by G. Dreyfuss), actin (Sigma;
A5316), tubulin (ab4074; Abcam), using peroxidase-conjugated secondary
antibodies and ECL detection reagent (Amersham). Secondary antibodies
were either polyclonal anti-rabbit (Cell Signaling; 7074) or anti-mouse (Bio-
Can; 115-035-003).
RNA Extraction and RT-PCR Analysis
Total RNA was extracted from treated or transfected cells with TRIzol (Invitro-
gen) as described by the manufacturer. The splicing profile of endogenous or
mini-gene-derived Bcl-x pre-mRNA was assessed by RT-PCR (Shkreta et al.,
2011). The RT-PCR analysis of other genes was performed by the RNomics
platform (Sherbrooke). Primers are listed in Table S6.
RNA Immunoprecipitation and qRT-PCR Analysis
EcR-293 cells treated with 20 mM oxaliplatin for 24 hr. After washing with PBS,
the cell pellet was resuspended into RIPA buffer supplemented with protease
and RNase inhibitors. Cells were lysed by sonication and the insoluble material
was removed by centrifugation at 4C. The supernatant was precleared by in-
cubation for 1 hr at 4C with Protein G Sepharose 4 Fast Flow beads (GEHealthcare) previously blocked with yeast tRNA. An aliquot of the precleared
supernatant was used as input while the remaining material was used for
immunoprecipitation. Precleared whole-cell lysates of equal protein quantities
were incubated overnight at 4C with protein G Sepharose beads coated with
antibodies against hnRNP F, H, K, and FLAG. Beads were collected by centri-
fugation at 1,300 3 g for 1 min, washed four times with RIPA buffer, resus-
pended in elution buffer (1% SDS, 5 mM EDTA, 10 mM DTT, 50 mM Tris-
HCl, pH 7.4). RNA was extracted using TRIzol, resuspended in 15 mL of
H2O, treatedwith DNase I for 15min at 37
C, and quantitated by spectrometry.
Equal quantities of RNA were reverse transcribed using M-MuLV enzyme and
the primer X-Int2-1-REV (CAG AGG CCA AAG AAA AGG GAC ACA) annealing
in intron 2 of Bcl-x. qPCR was carried out using SYBR green (23 Power SYBR
Green master mix; ABI; 4367660) and primers X-Int2-2-REV (CAC ACA AGG
GGC TTG GTT CTT A) and X-EX-S1-FWD (TCA CCC CAG GGA CAG CAT
ATC). The method used to determine the relative abundance of Bcl-x pre-
mRNA in immunoprecipitates compared Ct using the input sample (pre-
immunoprecipitated) as reference, while the difference between control and
oxaliplatin-treated samples was calculated using the 2DDCt method and
was expressed as fold change of Bcl-x pre-mRNA recovered from oxalipla-
tin-treated samples versus the non-treated control.
Protein Immunoprecipitation and Mass Spectrometry Analysis
EcR-293 cells expressing or not FLAG-SRSF10 and treated or not with ox-
aliplatin were cultured in 150-mm plates. Collected cells were washed two
times with ice-cold PBS and lysed on ice for 30 min in NET-2 buffer (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% [vol/vol] Nonidet P-40 added with
EDTA-free protease and phosphatase inhibitors cocktail [Roche Diagnos-
tics]). The clarified lysates were supplemented with RNase A solution
(0.1 mg/ml of cellular lysate) and incubated at room temperature for
30 min. Aliquots of SureBeads protein G magnetic beads (Bio-Rad) were
coupled with antibodies against hnRNP-F, H, K, or monoclonal anti-FLAG
M2 antibody (Sigma; F3165) through rotation for 1 hr at room temperature.
Equal aliquots of antibody-coupled beads were added to equal amounts of
protein containing pre-cleared cell lysates. After overnight incubation at
4C, beads were magnetized and washed four times with NET2 buffer.
Beads were resuspended in Laemmli buffer before gel fractionation. For
mass spectrometry analyses, beads were washed four times with 20 mM
NH4HCO3, resuspended in 50 mL of 20 mM NH4HCO3 buffer containing
1 mg of Trypsin Gold (Promega), and incubated overnight at 37C while
shaking. The reaction was stopped by adding formic acid (1% final). The
supernatant was transferred to a new tube, while beads were resuspended
in 50 mL of a solution containing 60% acetonitrile, 0.1% formic acid, and
incubated for 5 min at room temperature. Both supernatants were pooled
and lyophilized. Peptides were resuspended in 30 mL of 0.1% of trifluoro-
acetic acid and desalted using Zip Tip C18 (Millipore). Eluted peptides
were lyophilized and resuspended in 25 mL of 1% formic acid. Trypsin-di-
gested peptides loaded onto an Acclaim PepMap100 C18 column (Dionex
Corporation) were separated using a Dionex Ultimate 3000 nanoHPLC sys-
tem. The HPLC system was coupled to an OrbiTrap QExactive mass spec-
trometer (Thermo Fisher Scientific) via an EasySpray source. Data acquired
using the Xcalibur software were processed using the MaxQuant software
package, version 1.4.1.2, as described previously (Cox and Mann, 2008)
employing the Human Uniprot database.
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